OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function

Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist

(2018) Fanny Polesso et al.   Cancer Immunology Research

Roles of regulatory T cells in cancer immunity

(2016) Yoshiko Takeuchi et al.   INTERNATIONAL IMMUNOLOGY

Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ

(2016) Amy E. Moran et al.   JOURNAL OF IMMUNOLOGY

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

(2014) Yannick Bulliard et al.   IMMUNOLOGY AND CELL BIOLOGY

Effector T Cells Boost Regulatory T Cell Expansion by IL-2, TNF, OX40, and Plasmacytoid Dendritic Cells Depending on the Immune Context

(2014) Audrey Baeyens et al.   JOURNAL OF IMMUNOLOGY

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

(2013) Amy E Moran et al.   CURRENT OPINION IN IMMUNOLOGY

OX40 is required for regulatory T cell–mediated control of colitis

(2010) Thibault Griseri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right

(2009) C. E. Ruby et al.   JOURNAL OF IMMUNOLOGY

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

(2009) Kajsa Wing et al.   NATURE IMMUNOLOGY

OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor

(2008) M. J. Gough et al.   CANCER RESEARCH

Immune regulation and control of regulatory T cells by OX40 and 4-1BB

(2008) Takanori So et al.   CYTOKINE & GROWTH FACTOR REVIEWS

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

(2008) Silvia Piconese et al.   JOURNAL OF EXPERIMENTAL MEDICINE